UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
UBS analyst Joon Lee initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral rating and announces Price Target of $16.
UBS analyst Joon Lee initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral rating and announces Price Target of $16.